The unexpected consequences of asymmetric competition. An application to Big Pharma
The unexpected consequences of asymmetric competition. An application to Big Pharma
This paper shows that a pro-competitive shock leading to a steep price drop in one market segment may benefit substitute products. Consumers move away from the cheaper product and demand for the substitutes increases, possibly leading to a drop in consumer surplus. The channel leading to this outcome is non-price competition: the competitive shock on the first set of products decreases the firms' ability to invest in promotion, which cripples their ability to lure consumers. To assess the empirical relevance of these findings, we study the effects of generic entry into the pharmaceutical industry by exploiting a large product-level dataset for the US covering the period 1994Q1 to 2003Q4. We find strong empirical support for the model's theoretical predictions. Our estimates rationalize a surprising finding, namely that a molecule that loses patent protection (the originator drug plus its generic competitors) typically experiences a drop in the quantity market share-despite being sold at a fraction of the original price.
Ornaghi, Carmine
33275e47-4642-4023-a195-39c91d0146b0
Siotis, Georges
3de229c7-c594-4ed9-8da4-24ad57646695
Castanheira, Micael
ee506361-6cac-43df-bb2b-e008bc490254
January 2017
Ornaghi, Carmine
33275e47-4642-4023-a195-39c91d0146b0
Siotis, Georges
3de229c7-c594-4ed9-8da4-24ad57646695
Castanheira, Micael
ee506361-6cac-43df-bb2b-e008bc490254
Ornaghi, Carmine, Siotis, Georges and Castanheira, Micael
(2017)
The unexpected consequences of asymmetric competition. An application to Big Pharma
Record type:
Monograph
(Discussion Paper)
Abstract
This paper shows that a pro-competitive shock leading to a steep price drop in one market segment may benefit substitute products. Consumers move away from the cheaper product and demand for the substitutes increases, possibly leading to a drop in consumer surplus. The channel leading to this outcome is non-price competition: the competitive shock on the first set of products decreases the firms' ability to invest in promotion, which cripples their ability to lure consumers. To assess the empirical relevance of these findings, we study the effects of generic entry into the pharmaceutical industry by exploiting a large product-level dataset for the US covering the period 1994Q1 to 2003Q4. We find strong empirical support for the model's theoretical predictions. Our estimates rationalize a surprising finding, namely that a molecule that loses patent protection (the originator drug plus its generic competitors) typically experiences a drop in the quantity market share-despite being sold at a fraction of the original price.
This record has no associated files available for download.
More information
Published date: January 2017
Organisations:
Economics
Identifiers
Local EPrints ID: 410160
URI: http://eprints.soton.ac.uk/id/eprint/410160
PURE UUID: 840def62-4f68-4760-b0f7-2d4e8080c3c3
Catalogue record
Date deposited: 06 Jun 2017 04:01
Last modified: 16 Mar 2024 03:42
Export record
Contributors
Author:
Georges Siotis
Author:
Micael Castanheira
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics